| Date | Title | Description |
| 25.08.2026 | NIDA Grant Fuels PleoPharma's Groundbreaking Cannabis Addiction Treatment | PleoPharma secured a pivotal $6.5 million grant from the National Institute on Drug Abuse (NIDA). This funding accelerates its Phase 3 CAN-004 clinical trial. The trial investigates PP-01, a novel oral treatment for cannabis withdrawal symp... |
| 25.08.2026 | Thunder Compute Secures $13M to Unleash Dormant AI Power | Thunder Compute secured $13 million in Series A funding, led by Matrix Partners. The company addresses a critical industry problem: over $200 billion in idle GPU capacity, with enterprise utilization often below 5%. Its pioneering GPU virtu... |
| 21.08.2026 | PleoPharma Wins $6.5 Million NIDA Grant To Advance Phase 3 Cannabis Withdrawal Treatment | PleoPharma has received a $6.5 million, three-year grant from the National Institute on Drug Abuse to support its pivotal Phase 3 clinical program evaluating PP-01 as an investigational treatment for cannabis withdrawal symptoms in adults w... |
| 20.08.2026 | Thunder Compute Raises $13M in Series A Funding | Thunder Compute, a San Francisco, CA-based GPU virtualization and cloud infrastructure platform provider, raised $13m in Series A funding.
The round was led by Matrix Partners, with participation from Y Combinator and CEAS Investments.
The ... |
| 20.08.2026 | PleoPharma Receives $6.5M NIDA Grant | PleoPharma, a Phoenixville, PA-based clinical-stage development company focused on cannabis-related health issues, received a $6.5M grant from the National Institute on Drug Abuse (NIDA).
The company intends to use the funds to support the ... |
| 21.10.2025 | PleoPharma Closes $36M Series B Financing | PleoPharma, Inc., a Pheonixville, PA-based company focused on finding treatments for cannabis-related health issues, closed a $36M Series B financing round.
The backers were not disclosed.
Led by Ginger Constantine MD, co-founder and CEO, P... |
| 05.09.2024 | PLEOPHARMA, INC. REPORTS POSITIVE PHASE 2b CLINICAL TRIAL DATA FOR MITIGATION OF CANNABIS WITHDRAWAL: A POTENTIAL FIRST IN CLASS TREATMENT | Phase 2b Study for PP-01 Met Its Primary Endpoint
End of Phase 2 Meeting with FDA Completed
Phase 3 Preparations Underway
PHOENIXVILLE, Pa., Sept. 5, 2024 /PRNewswire/ -- PleoPharma, Inc., a privately held company focused on cannabis relate... |
| - | PleoPharma | “Pharmaceutical | PleoPharma | United States” |
